The ARHGAP32 Knockout HAP1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human cell line, designed for loss-of-function studies of the ARHGAP32 gene. This polyclonal knockout model disrupts ARHGAP32 expression across the cell pool, providing a robust tool for investigating Rho GTPase signaling dynamics without the biases of clonal selection. The heterogeneous nature of the polyclonal population supports functional assays that require a representative distribution of genetic edits, and it is well-suited for pooled CRISPR screens, high-throughput drug testing, and comparative gene function analyses.
The HAP1 cell line is a near-haploid, fibroblast-like cell model originally isolated from the KBM-7 chronic myeloid leukemia (CML) line. Its near-haploid karyotype simplifies genetic manipulation and phenotypic interpretation because each gene is typically represented by a single allele, streamlining knockout efficiency and reducing compensation by additional gene copies. HAP1 cells express wild-type TP53, adhere to standard cell culture surfaces, and are widely adopted for CRISPR-based functional genomics, particularly for knockout validation, genome-wide screens, and mechanistic cell biology studies. Their CML origin and stable, adherent growth make them a practical platform for dissecting signaling pathways relevant to both cancer and neuronal biology.
ARHGAP32 encodes a Rho GTPase-activating protein (RhoGAP) that negatively regulates Rho family small GTPases, including RhoA, Rac1, and Cdc42, by accelerating GTP hydrolysis to generate inactive GDP-bound forms. This activity directly modulates the actin cytoskeleton, thereby controlling cell morphology, migration, and adhesion. In neuronal contexts, ARHGAP32 functions as a scaffold protein linking NMDA receptors to the actin remodeling machinery through interactions with synaptic adaptors such as PSD-95 (DLG4) and SAP97 (DLG1). It is activated downstream of Eph receptor and integrin-mediated adhesion signaling, and its inactivation of RhoA/Rac1/Cdc42 suppresses downstream effectors like ROCK and PAK, ultimately inhibiting formin- and Arp2/3-driven actin polymerization. Through these interactions, ARHGAP32 couples extracellular guidance cues to cytoskeletal dynamics, impacting processes such as axonal outgrowth and dendritic spine morphogenesis.
Disruption of ARHGAP32 in the HAP1 polyclonal knockout population uncovers critical roles for this RhoGAP in actin-based processes without interference from functional gene copies. Given HAP1??s CML-derived background and its near-haploid genetics, this knockout model is particularly valuable for dissecting oncogenic signaling and cancer cell migration mechanisms, as well as for modeling aspects of neurodevelopmental disorders where ARHGAP32 mutations have been implicated. The loss of ARHGAP32-mediated GTPase inactivation is predicted to elevate levels of active RhoA, Rac1, and Cdc42, leading to increased actin polymerization and altered cell motility??phenotypes that can be rigorously tested in this clean genetic background. Additionally, the human origin of HAP1 ensures that the regulatory interactions with human-specific synaptic proteins are preserved, making it suitable for investigating schizophrenia-related pathways and other CNS biology.
Researchers can employ these ARHGAP32 knockout HAP1 polyclonal cells in a wide range of functional assays, including Rho GTPase activation assays (G-LISA), western blotting for active GTP-bound RhoA, Rac1, and Cdc42, and immunofluorescence imaging to visualize changes in actin filament organization. Cell migration and invasion assays, such as transwell or wound-healing experiments, are directly applicable to study the contribution of ARHGAP32 to cancer cell motility. Under appropriate differentiation conditions, neurite outgrowth measurements can be performed to examine its role in neuronal development. The polyclonal pool is also amenable to co-immunoprecipitation for mapping protein interactions with synaptic scaffolding molecules like PSD-95, as well as to drug target validation studies for cancer and neuropsychiatric disorders. For further information and technical support, please contact Ascent Research.
